Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,18234062,doubling time,"Three patients with ADPC had a greater than three-fold increase in PSA doubling time while on therapy, one from 11 to 46 months (750 mg), one from 9.5 to 49.5 months (1750 mg), and one from 5.9 to 46.2 months (2500 mg).",A pilot dose-escalation study of the effects of nordihydroguareacetic acid on hormone and prostate specific antigen levels in patients with relapsed prostate cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18234062/),month,11 to 46,9556,DB00179,Masoprocol
,18234062,doubling time,"Three patients with ADPC had a greater than three-fold increase in PSA doubling time while on therapy, one from 11 to 46 months (750 mg), one from 9.5 to 49.5 months (1750 mg), and one from 5.9 to 46.2 months (2500 mg).",A pilot dose-escalation study of the effects of nordihydroguareacetic acid on hormone and prostate specific antigen levels in patients with relapsed prostate cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18234062/),month,9.5 to 49.5,9557,DB00179,Masoprocol
,18234062,doubling time,"Three patients with ADPC had a greater than three-fold increase in PSA doubling time while on therapy, one from 11 to 46 months (750 mg), one from 9.5 to 49.5 months (1750 mg), and one from 5.9 to 46.2 months (2500 mg).",A pilot dose-escalation study of the effects of nordihydroguareacetic acid on hormone and prostate specific antigen levels in patients with relapsed prostate cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18234062/),month,5.9 to 46.2,9558,DB00179,Masoprocol
,11318430,limit of detection,The limit of detection of this method was 0.5 microg/ml.,Pharmacokinetic analysis by high-performance liquid chromatography of intravenous nordihydroguaiaretic acid in the mouse. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11318430/),[μg] / [ml],0.5,51241,DB00179,Masoprocol
,11318430,peak plasma concentration,"Administration of NDGA (50 mg/kg, i.v.) to mice resulted in a peak plasma concentration of 14.7 microg/ml.",Pharmacokinetic analysis by high-performance liquid chromatography of intravenous nordihydroguaiaretic acid in the mouse. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11318430/),[μg] / [ml],14.7,51242,DB00179,Masoprocol
,11318430,terminal half-life,The terminal half-life of NDGA was 135.0 min with a clearance of 201.9 ml/min x kg.,Pharmacokinetic analysis by high-performance liquid chromatography of intravenous nordihydroguaiaretic acid in the mouse. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11318430/),min,135.0,51243,DB00179,Masoprocol
,11318430,clearance,The terminal half-life of NDGA was 135.0 min with a clearance of 201.9 ml/min x kg.,Pharmacokinetic analysis by high-performance liquid chromatography of intravenous nordihydroguaiaretic acid in the mouse. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11318430/),[ml] / [kg·min],201.9,51244,DB00179,Masoprocol
,22323663,overall median survival,The overall median survival was 5.9 months.,Phase I study of terameprocol in patients with recurrent high-grade glioma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22323663/),month,5.9,142870,DB00179,Masoprocol
